Overview

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
Phase:
Phase 1
Details
Lead Sponsor:
Response Pharmaceuticals